M2GEN announced a significant new investment by Clayton, Dubilier & Rice funds, the Merck Global Health Innovation Fund and McKesson Ventures to recapitalize M2GEN, a leading oncology data and informatics platform focused on transforming cancer care, in partnership with its existing shareholders.